I think many UK investors aren't thinking sales World Wide here. Esp in America where there is no NHS. If you have chance to by an SNG inhaler for your mother you would. Every COPD, asthma or lung disease person will be having prescriptions for Interferfon to prevent and lessen the impact of ANY flu or cold, let alone this strain. Around the world people are already being treated with interferon. Its known to be effective hence why it is currently being used. The professors, doctors and MHRA and FDA and WHO all pin their hopes on this as a treatment. This will be a standard drug for people with lung disease available on prescription a few times a year. It will be an absolute smash hit.
Lets not be candid. The MHRA would not let clinical trials be expidited unless it fully expected this proven technology to work and be approved, neither would the WHO. The fact Astrazeneca are already partnered up gives you an idea where this is going. Lets hope the drug can be used urgently and save our mums, dad and grandparents.
Worth topping up on and BYOT. Can see other companies following Tristels lead and getting Byotrols License atleast for one or 2 of their product lines. Should be strong rises in infection control. May spike in a few weeks or months.
Indeed. The IP on this is great. 24hr protection. Used in hospitals, food industry, veterinary. Its the licensed polymer that is so effective. In terms of time. If you can get one clean done per day rather than 3 you save on wages and staff. The fact that its passed all the ENs and will be used by Tristel, is sold in Boots, was or will be in Tesco's. The potential of all other manufactures to add a line to their product range that contains the polymer is massive. Already partnered with Solvay and Tristel. I can only wish Id bought it cheaper. The hand gel is already used by the NHS and the products are on the supply chain. This is one no brainer